GILD 50.50 -0.13 / Gilead Sciences, Inc. FDA | Benzinga

Monday, May 21, 2012

The Definitive Biotech ETF Guide (IBB, XBI, FBT) (ABT, AFFY, AMGN, AMLN, Analyst Color, BBH, CBST, CELG, FBT, GILD, IBB, INCY, Long Ideas, News, PBE, PFE, PJP, PSCH, QCOR, Sector ETFs, SLXP, VRTX, XBI, Short Ideas, Rumors, Small Cap Analysis, FDA, M&A, Events, Intraday Update, Markets, Analyst Ratings, Movers, Trading Ideas, ETFs / Mon, 01:35pm)

Tuesday, May 15, 2012

S&P Bullish On Biotech ETFs (FBT, IBB, XBI) (ABT, AFFY, AMGN, AMLN, Analyst Color, FBT, GILD, IBB, INCY, Long Ideas, MRK, News, PFE, PJP, Sector ETFs, VRTX, XBI, Short Ideas, Rumors, FDA, M&A, Intraday Update, Markets, Analyst Ratings, Trading Ideas, ETFs / Tue, 02:31pm)

Friday, May 11, 2012

UPDATE: FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV (GILD, News, FDA / Fri, 03:31pm)
From Earlier: FDA Advisory Committee Supports Approval of Gilead's Truvada® for Reducing the Risk of Acquiring HIV (GILD, News, FDA / Fri, 08:52am)

Thursday, April 19, 2012

Notable Options Activity in Gilead Sciences Inc (GILD, News, Options, FDA, Markets, Trading Ideas / Thu, 10:13am)
Financial Breakfast: Morning News Summary for April 19, 2012 (BAC, Bonds, CHK, CVI, DD, Earnings, EBAY, FFIV, GILD, GSK, HGSI, LUV, MS, News, PM, Futures, Guidance, Upgrades, Commodities, Downgrades, Forex, Technicals, FDA, M&A, Events, Global, Economics, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, General / Thu, 07:38am)
From Earlier: Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients (GILD, News, FDA / Thu, 07:22am)

Wednesday, March 07, 2012

Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study (GILD, News, FDA / Wed, 04:01pm)

Friday, February 17, 2012

Friday Slide: Opportunity Or Red Flag For Biotech ETFs? (GILD, IBB, XBI) (AAPL, AMGN, BBH, FBT, GILD, GOOG, IBB, LIFE, Long Ideas, News, QQQ, Sector ETFs, XBI, Short Ideas, Specialty ETFs, FDA, Intraday Update, Markets, Movers, Trading Ideas, ETFs / Fri, 04:10pm)
Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish (ACHN, Analyst Color, BMY, C, GILD, IDIX, JPM, News, VRTX, Small Cap, FDA, Events, Intraday Update, Analyst Ratings, Movers / Fri, 01:30pm)
UPDATE: Analyst Mark Schoenebaum Discusses Gilead Sciences on CNBC (CNBC, GILD, Long Ideas, News, Short Ideas, FDA, Media, Trading Ideas / Fri, 11:29am)
Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix (ACHN, Analyst Color, GILD, IDIX, News, VRTX, FDA, Pre-Market Outlook, Analyst Ratings, Movers / Fri, 08:54am)
Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study; Viral Relapse Seen Post Treatment with GS-7977 Plus Ribavirin (GILD, News, FDA / Fri, 07:52am)

Tuesday, February 14, 2012

From Earlier: U.S. FDA Grants Priority Review for Truvada for Reducing the Risk of Acquiring HIV Infection (GILD, News, FDA / Tue, 10:10am)

Friday, February 03, 2012

Gilead Sciences Soars On "Striking" Clinical Trial Data (Analyst Color, Earnings, GILD, JPM, Long Ideas, News, Guidance, Short Ideas, Price Target, FDA, Intraday Update, Markets, Analyst Ratings, Movers, Trading Ideas / Fri, 02:33pm)

Tuesday, January 24, 2012

Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV (GILD, News, FDA / Tue, 05:06pm)
BioLineRx Surges after Hep C License Agreement (BLRX, BMY, GILD, INHX, News, VRUS, Contracts, FDA, M&A, Intraday Update, Movers / Tue, 11:23am)

Thursday, January 19, 2012

From Earlier: Gilead Sciences Announces U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV (GILD, News, FDA / Thu, 07:54am)

Monday, January 09, 2012

Just What The Doctor Ordered: 4 ETFs For Biotech M&A (ACHN, AFFX, ALXN, AMGN, BBH, BIIB, BMRN, BMY, CELG, DNDN, FBT, GILD, IDIX, INHX, ITMN, Long Ideas, News, PSCH, REGN, Sector ETFs, XBI, Short Ideas, Specialty ETFs, New ETFs, Rumors, Small Cap Analysis, Technicals, FDA, M&A, Events, Intraday Update, After-Hours Center, Markets, Movers, Trading Ideas, ETFs / Mon, 04:49pm)
Forget Dendreon, Inhibitex is the New Biotech Success Story (ACHN, BMY, Earnings, GILD, IDIX, INHX, News, VRUS, Guidance, Small Cap, FDA, M&A, Events, Trading Ideas / Mon, 02:26pm)

Tuesday, December 20, 2011

Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infectio (GILD, News, FDA / Tue, 05:30pm)

Thursday, December 15, 2011

Gilead Sciences Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Truvada (GILD, News, FDA / Thu, 05:30pm)

Friday, December 09, 2011

Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV (GILD, News, FDA / Fri, 09:42am)

Monday, December 05, 2011

Deutsche Bank Reiterates Buy, $53 PT on Gilead (Analyst Color, GILD, News, Reiteration, FDA, Intraday Update, Markets, Analyst Ratings, Movers / Mon, 01:16pm)
Citi Reiterates Buy, $49 PT on Gilead (Analyst Color, GILD, News, VRUS, Price Target, Reiteration, FDA, Intraday Update, Markets, Analyst Ratings, Movers, Trading Ideas / Mon, 01:11pm)
J.P. Morgan Reiterates Overweight On Gilead (Analyst Color, GILD, News, VRUS, Reiteration, FDA, Intraday Update, Markets, Analyst Ratings, Movers, Trading Ideas / Mon, 01:07pm)
Gilead's Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study (GILD, News, FDA / Mon, 09:33am)

Tuesday, November 29, 2011

Brean Murray Raises Inhibitex PT to $19 From $12 (Analyst Color, GILD, INHX, Long Ideas, News, VRUS, Price Target, Reiteration, FDA, Intraday Update, Markets, Analyst Ratings, Trading Ideas / Tue, 01:25pm)

Monday, November 28, 2011

Gilead Receives European Marketing Authorization for Eviplera (GILD, News, FDA / Mon, 02:00pm)
Deutsche Bank Has Buy, $53 PT On Gilead (Analyst Color, GILD, News, VRUS, Price Target, Reiteration, FDA, M&A, Intraday Update, Markets, Analyst Ratings, Trading Ideas / Mon, 12:37pm)

Tuesday, November 22, 2011

Brean Murray Downgrades Pharmasset to "Hold" (Analyst Color, GILD, News, VRUS, Downgrades, Price Target, FDA, M&A, Intraday Update, Markets, Analyst Ratings, Movers, Trading Ideas / Tue, 12:29pm)

Monday, November 21, 2011

Hep-C Stocks Soar On M&A News (ACHN, BMY, GILD, INHX, Long Ideas, News, VRTX, VRUS, Short Ideas, Rumors, FDA, M&A, Hot, Intraday Update, Markets, Trading Ideas / Mon, 02:14pm)
Financial Breakfast: Morning News Summary for November 21, 2011 (BYI, Earnings, FSIN, GILD, Long Ideas, MYL, News, REGN, TECD, TGT, TRH, TSN, VRUS, WAL, Y, Futures, Guidance, Short Ideas, Upgrades, Commodities, Downgrades, Forex, Technicals, FDA, M&A, Events, Global, Econ #s, Economics, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, General / Mon, 08:34am)

Tuesday, November 15, 2011

Monday, November 07, 2011

Gilead Sciences and Cardiovascular Research Foundation Initiate Phase 3 Clinical Trial with Ranolazine in Patients Who Have Undergone PCI with a History of Prior Chronic Angina (GILD, News, FDA / Mon, 09:33am)